Hypoxia and Hypoxia-Inducible Factors in Lymphedema

Xinguo Jiang; Wen Tian; Dongeon Kim; Alexander S McQuiston; Ryan Vinh; Stanley G Rockson; Gregg L Semenza; Mark R Nicolls

doi:10.3389/fphar.2022.851057

Hypoxia and Hypoxia-Inducible Factors in Lymphedema

Front Pharmacol. 2022 Mar 28:13:851057. doi: 10.3389/fphar.2022.851057. eCollection 2022.

Authors

Xinguo Jiang^{1

2}, Wen Tian^{1

2}, Dongeon Kim^{1

2}, Alexander S McQuiston^{1

2}, Ryan Vinh^{1

2}, Stanley G Rockson², Gregg L Semenza³, Mark R Nicolls^{1

2}

Affiliations

¹ VA Palo Alto Health Care System, Palo Alto, CA, United States.
² Stanford University School of Medicine, Stanford, CA, United States.
³ Departments of Pediatrics, Medicine, Oncology, Radiation Oncology, and Biological Chemistry, and McKusick-Nathans Institute of Genetic Medicine, Vascular Program, Institute for Cell Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, United States.

Abstract

Lymphedema is a chronic inflammatory disorder characterized by edema, fat deposition, and fibrotic tissue remodeling. Despite significant advances in lymphatic biology research, our knowledge of lymphedema pathology is incomplete. Currently, there is no approved pharmacological therapy for this debilitating disease. Hypoxia is a recognized feature of inflammation, obesity, and fibrosis. Understanding hypoxia-regulated pathways in lymphedema may provide new insights into the pathobiology of this chronic disorder and help develop new medicinal treatments.

Keywords: HIF; hypoxia; inflammation; lymphangiogensis; lymphedema.

Publication types

Review

Abstract

Publication types

Grants and funding